» Articles » PMID: 30911936

Advances, Challenges, and Perspectives in Translational Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Overview
Journal Mol Neurobiol
Date 2019 Mar 27
PMID 30911936
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Finding an effective therapeutic approach is a primary goal for current and future research for amyotrophic lateral sclerosis (ALS), a fatal neurological disease characterized by degeneration and loss of upper and lower motor neurons. Transplantation approaches based on stem cells have been attempted in virtue of their potential to contrast simultaneously different ALS pathogenic aspects including either the replacement of lost cells or the protection of motor neurons from degeneration and toxic microenvironment. Here, we critically review the recent translational research aimed at the assessment of stem cell transplantation safety and feasibility in the treatment of ALS. Most of these efforts aim to exert a neuroprotective action rather than cell replacement. Critical aspects that emerge in these studies are the need for the identification of the most effective therapeutic cell source (mesenchymal stem cells, immune, or neural stem cells), the definition of the optimal injection site (cortical area, spinal cord, or muscles) with a suitable administration protocol (local or systemic injection), and the analysis of therapeutic mechanisms, which are necessary steps in order to overcome the hurdles posed by previous in vivo human studies. New perspectives will also be offered by the increasing number of induced pluripotent stem cell-based therapies that are now being tested in clinical trials. A thorough analysis of recently completed trials is the foundation for continued progress in cellular therapy for ALS and other neurodegenerative disorders.

Citing Articles

Proteomic analysis of cerebrospinal fluid of amyotrophic lateral sclerosis patients in the presence of autologous bone marrow derived mesenchymal stem cells.

Reis A, Maximino J, Lage L, Gomes H, Pereira J, Brofman P Stem Cell Res Ther. 2024; 15(1):301.

PMID: 39278909 PMC: 11403799. DOI: 10.1186/s13287-024-03820-2.


Intranasal delivery of small extracellular vesicles reduces the progress of amyotrophic lateral sclerosis and the overactivation of complement-coagulation cascade and NF-ĸB signaling in SOD1 mice.

Zhou J, Li F, Jia B, Wu Z, Huang Z, He M J Nanobiotechnology. 2024; 22(1):503.

PMID: 39174972 PMC: 11340036. DOI: 10.1186/s12951-024-02764-2.


The Fingerprints of Biomedical Science in Internal Medicine.

Arjmand B, Alavi-Moghadam S, Sarvari M, Tayanloo-Beik A, Aghayan H, Mehrdad N Adv Exp Med Biol. 2022; 1401:173-189.

PMID: 35856133 DOI: 10.1007/5584_2022_729.


Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases.

Abati E, Manini A, Comi G, Corti S Cell Mol Life Sci. 2022; 79(7):374.

PMID: 35727341 PMC: 9213329. DOI: 10.1007/s00018-022-04408-w.


Human ESC-derived immunity- and matrix- regulatory cells ameliorated white matter damage and vascular cognitive impairment in rats subjected to chronic cerebral hypoperfusion.

Zhao Y, Wu J, Li D, Liu J, Chen W, Hou Z Cell Prolif. 2022; 55(5):e13223.

PMID: 35437845 PMC: 9136497. DOI: 10.1111/cpr.13223.


References
1.
Freed C, Greene P, Breeze R, Tsai W, DuMouchel W, Kao R . Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001; 344(10):710-9. DOI: 10.1056/NEJM200103083441002. View

2.
Kaspar B, Llado J, Sherkat N, Rothstein J, Gage F . Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003; 301(5634):839-42. DOI: 10.1126/science.1086137. View

3.
Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C . Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4(3):158-61. DOI: 10.1080/14660820310014653. View

4.
Clement A, Nguyen M, Roberts E, Garcia M, Boillee S, Rule M . Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003; 302(5642):113-7. DOI: 10.1126/science.1086071. View

5.
Corti S, Locatelli F, Donadoni C, Guglieri M, Papadimitriou D, Strazzer S . Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain. 2004; 127(Pt 11):2518-32. DOI: 10.1093/brain/awh273. View